Skip to main content
. 2021 Sep 20;12:742631. doi: 10.3389/fimmu.2021.742631

Figure 5.

Figure 5

Analysis of ADCC activity in a subgroup of patients with different presentations of COVID-19 and their levels of IgGs against SARS-CoV-2 and prevalent herpesviruses. (A) Analysis of ADCC assay by quantification of Annexin V-PE as a measurement of apoptosis in PKH76-labelled, rituximab-coated Raji cells after co-culture with PBMCs (1:2) isolated from patients with mild, severe and critical COVID-19. Titers of total IgGs (B) and neutralizing antibodies, calculated as ID50 (C), against SARS-CoV-2 spike protein in plasma from the same patients. Titers of IgGs against CMV (D), HSV-1 (E), EBV (F), and VZV (G) in plasma from the same patients. Data shown are mean ± SEM. Statistical significance was calculated using one-way ANOVA and Tukey’s multiple comparisons test. **p < 0.01, ****p < 0.001.